BridgeBio is significantly boosted its development of an innovative therapy for cardiac amyloidosis, leveraging the investigational drug. Early trial results indicates promising outcomes for individuals affected by this https://attrcm478181.mybuzzblog.com/22232123/company-advances-amyloidosis-therapy-through-the-drug